These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 24637915)

  • 1. MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression.
    Hu Y; Zhu Q; Tang L
    PLoS One; 2014; 9(3):e92099. PubMed ID: 24637915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-99a Inhibits Cell Proliferation and Tumorigenesis through Targeting mTOR in Human Anaplastic Thyroid Cancer.
    Huang HG; Luo X; Wu S; Jian B
    Asian Pac J Cancer Prev; 2015; 16(12):4937-44. PubMed ID: 26163618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma.
    Cui L; Zhou H; Zhao H; Zhou Y; Xu R; Xu X; Zheng L; Xue Z; Xia W; Zhang B; Ding T; Cao Y; Tian Z; Shi Q; He X
    BMC Cancer; 2012 Nov; 12():546. PubMed ID: 23173671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-99a Enhances the Radiation Sensitivity of Non-Small Cell Lung Cancer by Targeting mTOR.
    Yin H; Ma J; Chen L; Piao S; Zhang Y; Zhang S; Ma H; Li Y; Qu Y; Wang X; Xu Q
    Cell Physiol Biochem; 2018; 46(2):471-481. PubMed ID: 29614485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-99a-5p inhibits bladder cancer cell proliferation by directly targeting mammalian target of rapamycin and predicts patient survival.
    Liu Y; Li B; Yang X; Zhang C
    J Cell Biochem; 2019 Dec; 120(12):19330-19337. PubMed ID: 30560585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-99a directly targets the mTOR signalling pathway in breast cancer side population cells.
    Yang Z; Han Y; Cheng K; Zhang G; Wang X
    Cell Prolif; 2014 Dec; 47(6):587-95. PubMed ID: 25348507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-15/16 complex targets p70S6 kinase 1 and controls cell proliferation in MDA-MB-231 breast cancer cells.
    Janaki Ramaiah M; Lavanya A; Honarpisheh M; Zarea M; Bhadra U; Bhadra MP
    Gene; 2014 Dec; 552(2):255-64. PubMed ID: 25261849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel small-molecule compound diaporine A inhibits non-small cell lung cancer growth by regulating miR-99a/mTOR signaling.
    Song Y; Dou H; Wang P; Zhao S; Wang T; Gong W; Zhao J; Li E; Tan R; Hou Y
    Cancer Biol Ther; 2014 Oct; 15(10):1423-30. PubMed ID: 25046358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.
    Nawroth R; Stellwagen F; Schulz WA; Stoehr R; Hartmann A; Krause BJ; Gschwend JE; Retz M
    PLoS One; 2011; 6(11):e27509. PubMed ID: 22110663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
    BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway.
    Li G; Shan C; Liu L; Zhou T; Zhou J; Hu X; Chen Y; Cui H; Gao N
    PLoS One; 2015; 10(2):e0117440. PubMed ID: 25659153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-99 family targets AKT/mTOR signaling pathway in dermal wound healing.
    Jin Y; Tymen SD; Chen D; Fang ZJ; Zhao Y; Dragas D; Dai Y; Marucha PT; Zhou X
    PLoS One; 2013; 8(5):e64434. PubMed ID: 23724047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma.
    Sun J; Chen Z; Tan X; Zhou F; Tan F; Gao Y; Sun N; Xu X; Shao K; He J
    Med Oncol; 2013 Mar; 30(1):411. PubMed ID: 23292834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of rapamycin sensitivity in breast cancer cells.
    Noh WC; Mondesire WH; Peng J; Jian W; Zhang H; Dong J; Mills GB; Hung MC; Meric-Bernstam F
    Clin Cancer Res; 2004 Feb; 10(3):1013-23. PubMed ID: 14871980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways.
    Li XJ; Luo XQ; Han BW; Duan FT; Wei PP; Chen YQ
    Br J Cancer; 2013 Oct; 109(8):2189-98. PubMed ID: 24030073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Li YJ; Wang Y; Wang YY
    J Cell Physiol; 2019 Jun; 234(6):9577-9591. PubMed ID: 30480801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of long non-coding RNA ANRIL inhibits tumorigenesis in human gastric cancer cells via microRNA-99a-mediated down-regulation of BMI1.
    Liu P; Zhang M; Niu Q; Zhang F; Yang Y; Jiang X
    Braz J Med Biol Res; 2018 Aug; 51(10):e6839. PubMed ID: 30156609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.
    Oneyama C; Ikeda J; Okuzaki D; Suzuki K; Kanou T; Shintani Y; Morii E; Okumura M; Aozasa K; Okada M
    Oncogene; 2011 Aug; 30(32):3489-501. PubMed ID: 21383697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
    Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
    Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development.
    Cheng H; Xue J; Yang S; Chen Y; Wang Y; Zhu Y; Wang X; Kuang D; Ruan Q; Duan Y; Wang G
    Oncotarget; 2017 Jul; 8(29):47984-47997. PubMed ID: 28624790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.